Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of Trametinib Use in BRAF-Negative Juvenile Histiocytosis
2020-005053-25Phase 2Active
- Sponsor
- Institute of Mother and Child
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trametinib in histiocytosis, Langerhans cell histiocytosis (LCH) and histiocytic disease, sponsored by Institute of Mother and Child. Primary endpoint: Event-free survival. Started Jan 2021; status: active.
02
Drugs
trametinib
03
Conditions
histiocytosisLangerhans cell histiocytosis (LCH)histiocytic disease
Beyond the preview
Go deeper on 2020-005053-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005053-25.